MRD / Regn No. : 20220000684 Date : 01/07/2026
Patient Name : Doss Natarajan Age & Gender : 46 Yrs. / Male
Contact No. : 9841888632 UHID :
Ht / Wt / BMI : 169.5 / 90.0 / 31.33 BP S / BP D : 110 / 73
Allergies : NKA Referred By :
   
Problem List : TYPE 2 DM (21/Jun/2022) | A2G1 DKD (21/Jun/2022) | DYSLIPIDEMIA (21/Jun/2022) | NAFLD (22/Jul/2022) |
Subjective : NO NEW COMPLAINTS
Objective : NONE
Analysis : A2G1DKD,DYSLIPIDEMIA,TYPE 2 DM IMPROVING CONTROL,NAFLD S2F1
Plan : SWITCH TO INJECTABLE GLP1RA,SEE ME IN 2 MONTHS WITH TESTING,INCREASE SEMAGLUTIDE 1.7 MG  
Salient Investigations : FASTING PLASMA GLUCOSE (FPG): 98.8 mg/dL | POST PRANDIAL GLUCOSE (2HPP): 114 mg/dL
S# Generic (Trade) Name Route Dosage Usage Duration
1 TELMISARTAN 40 MG
ERITEL 40 MG
Medicine For HYPERTENSION KIDNEY PROTECTION 		PO 0-0-1 AT BEDTIME
 TILL NEXT VISIT
MAY CAUSE HIGH POTASSIUM
2 ROSUVASTATIN 10 MG
ROSEDAY 10 MG
Medicine For CHOLESTEROL 		PO 0-0-1 AT BEDTIME
 TILL NEXT VISIT
MAY CAUSE FATIGUE AND MUSCLE PAIN
3 TABLET DAPAGLIFLOZIN 10 MG
GLUXIT
Medicine For DIABETES OBESITY HEART AND KIDNEY PROTECTION 		PO 1-0-0 BEFORE FOOD SEE INSTRUCTIONS AND PRECAUTIONS IN EDUCATION
 TILL NEXT VISIT
MAY CAUSE GENITOURINARY INFECTIONS
4 INJECTION SEMAGLUTIDE 1.7 MG
SEMBOLIC 1.7 MG
Medicine For DIABETES OBESITY 		SQ ONCE A WEEK AS DIRECTED NO RELATION TO FOOD
MAY CAUSE NAUSEA VOMITING AND VISION DISTURBANCE
       
Refill : 0 / Substitution:    
Education :
Next Visit : 30/Aug/2026
Tests Suggested For Next Visit : FBS 2HPP HBA1C
   
   

Dr. Krishna G Seshadri
Sr. Consultant Endocrinology Diabetes and Metabolism
Tamil Nadu / 48748 HPRID: 71-0638-2075-7542

This is a Computer generated Prescription

Powered By: